Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3031207 + simvastatin
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Oral
01
Overview
LY3031207 + simvastatin is a combination therapy involving LY3031207, an investigational antisense oligonucleotide (ASO) targeting angiopoietin-like 3 (ANGPTL3) mRNA, and simvastatin, a standard-of-care HMG-CoA reductase inhibitor (statin). LY3031207 was developed by Eli Lilly to inhibit the hepatic production of ANGPTL3, a protein that regulates lipid metabolism by inhibiting lipoprotein lipase and endothelial lipase. By reducing ANGPTL3 levels, the drug aims to lower triglycerides and LDL cholesterol. Simvastatin acts by inhibiting the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing endogenous cholesterol production. The combination was primarily evaluated in clinical trials to assess the safety, pharmacokinetics, and potential additive lipid-lowering effects in patients with hypercholesterolemia. Eli Lilly discontinued the development of LY3031207 in 2019.
- Other names
- LY3031207 and simvastatinLY-3031207 and simvastatinLY 3031207 and simvastatin
02
Targets
PTGES (Microsomal prostaglandin E synthase-1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on LY3031207 + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3031207 + simvastatin.